Reduction of four-and-a-half LIM-protein 2 expression occurs in human left ventricular failure and leads to altered localization and reduced activity of metabolic enzymes  by Bovill, Esta et al.
A
C
D
Bovill et al Acquired Cardiovascular DiseaseReduction of four-and-a-half LIM-protein 2 expression occurs in
human left ventricular failure and leads to altered localization and
reduced activity of metabolic enzymes
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Objective:We sought to identify changes in four-and-a-half LIM-protein 2 levels and location in human cardi-
omyocytes during the transition from compensated aortic stenosis to left ventricular failure. We also sought to
characterize four-and-a-half LIM-protein 2 binding with the metabolic enzymes phosphofructokinase 2, adeny-
late kinase, and creatine kinaseM isoform during this transition and their consequential subcellular localization in
failing human ventricles.
Methods: Left ventricular biopsy specimens from selected patients undergoing aortic valve replacement for aor-
tic stenosis were allocated to one of 2 groups: (1) nondilated with preserved left ventricular function (nonfailing
group, n¼ 16) and (2) grossly dilated with poor left ventricular function (failing group, n¼ 15). These were com-
pared with a control group of unused donor hearts (n ¼ 6). Protein levels and subcellular localization were de-
termined by means of Western blotting and immunofluorescence. Four-and-a-half LIM-protein 2 binding to
adenylate kinase, creatine kinase M isoform, or phosphofructokinase 2 was studied by means of coimmuno-
precipitation. Phosphofructokinase 2, adenylate kinase, and creatine kinase M isoform activities were assayed
in protein extractions.
Results: Four-and-a-half LIM-protein 2 levels were preserved in nonfailing hypertrophied hearts but reduced by
53% in failing hearts. The pattern of four-and-a-half LIM-protein 2 staining was disrupted in failing hearts: four-
and-a-half LIM-protein 2 was lost from the sarcomere but present in the perinuclear Golgi apparatus complex.
Phosphofructokinase 2, adenylate kinase, and creatine kinase M isoform coimmunoprecipitated in vitro and co-
localized with four-and-a-half LIM-protein 2 in both hypertrophied and failing hearts. Phosphofructokinase 2 and
adenylate kinase activities were reduced to 77% and 58% of normal values in compensated aortic stenosis, with
phosphofructokinase 2 activity decreased further to 56% of normal value in failing hearts, but creatine kinase
activity remained unchanged.
Conclusions: Altered four-and-a-half LIM-protein 2 expression in heart failure is associated with disruption of
the normal subcellular localization of phosphofructokinase 2, adenylate kinase, and creatine kinase M isoform
and reduced activity of phosphofructokinase 2 and adenylate kinase, which might have important consequences
for myocardial energy metabolism in heart failure.Clinical decision making regarding the optimal timing for
aortic valve replacement is an inexact science. At the time
of clinical presentation, patients with aortic stenosis already
manifest a broad spectrum of myocardial functional change.
Left ventricular (LV) morphology ranges from asymptom-
atic compensatory hypertrophy to cavity dilation with symp-
toms of advanced heart failure. During valve replacement
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doi:10.1016/j.jtcvs.2008.09.006The Journal of Thoracic and Csurgery, impaired LV function can negatively influence sur-
vival,1 particularly when myocardial energetics might have
already deteriorated before the period of ischemic arrest. Ac-
cess to human myocardium during surgical intervention pro-
vides a unique opportunity to correlate myocyte molecular
changes to the LV phenotype, which can be characterized
beforehand by means of detailed cardiac imaging.
Abnormal recruitment of metabolic enzymes to the car-
diac sarcomere, via known interactions between sarcomeric
proteins and stretch-dependent signaling molecules may
play an important role in the deterioration of myocardial
function in heart failure.2,3 Four-and-a-half LIM-protein 2
(FHL2) is thought to act as a specific adaptor protein cou-
plingmetabolic enzymes to sites of high energy consumption
in the sarcomere through interaction with titin/connectin.4
Titin forms an elastic scaffold spanning more than 1 mm
from a Z-disc to the M-band.4 Localization of metabolic en-
zymes to metabolically active regions within the sarcomere
is necessary for energy provision during contraction.5 Muta-
tions inFHL2 have already been identified as predisposing toardiovascular Surgery c Volume 137, Number 4 853
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ADP ¼ adenosine diphosphate
AK ¼ adenylate kinase
ATP ¼ adenosine triphosphate
ATPase ¼ adenosine triphosphatase
CK-M ¼ creatine kinase isoform M
DAPI ¼ 40-6-Diamidino—2-phenylindole,
dihydrochloride
ERK ¼ extracellular signal-regulated kinase
FHL2 ¼ four-and-a-half LIM-protein 2
LV ¼ left ventricular
PBS ¼ phosphate-buffered saline
PFK2 ¼ phosphofructokinase 2
SDS ¼ sodium dodecylsulfate
idiopathic dilated cardiomyopathy.2 Studies in cardiac sar-
comeres have shown FHL2 localized to broad striations at
the Z-disk.4 This distinctly localized FHL2 couples adeny-
late kinase (AK), creatine kinase isoform M (CK-M), and
phosphofructokinase 2 (PFK2) to titin.4
Cardiac contraction requires efficient energetics. Commu-
nication defects between adenosine triphosphate (ATP)–
producing and ATP-consuming sites are a major contributor
to deficient energetics in heart failure. Reduced activity of
CK, AK, and glycolytic enzymes, which collectively facili-
tate ATP delivery and promote removal of adenosine di-
phosphate (ADP), Pi, and Hþ from cellular adenosine
triphosphatases (ATPases), has been described in the failing
heart.6 Energy transfer through AK, CK, and glycolytic en-
zymes is an adaptive mechanism, but the compensatory po-
tential of these systems is reduced in the failing heart.6
In the failing heart the overall ATP turnover rate is similar
to the normal value, but there are changes in the kinetics of
ATP use, suggesting that a smaller ATP pool is involved.6
This could result from an altered localization or deficient
phosphotransfer of adenine nucleotides.7 Decreased ener-
getic efficiency has been observed in CK–knockout hearts,8
which supports a critical role for phosphotransfer reactions
in myocardial energetics.6
PFK2 is a bifunctional enzyme that controls the synthesis
and degradation of fructose 2,6-bisphosphate. Fructose 2,6-
bisphosphate is a potent stimulator of 6-phosphofructo-1-
kinase, a key glycolytic enzyme. Cardiac PFK2 is activated
by adrenaline, insulin, or high workload. This correlates
with increased glycolysis under the same conditions.9
PFK2 levels or activity have not been measured in heart fail-
ure, but reduced PFK2 activity could reduce glycolytic flux,
resulting in impaired cardiac function. Because FHL2 is
known to couple PFK2, AK, and CK-M to titin at metabol-
ically active regions within the sarcomere, we sought to fur-
ther investigate this adaptor role in human myocardium854 The Journal of Thoracic and Cardiovascular Sutaken from healthy hearts, together with hearts from patients
with aortic stenosis but normal contractility, and myocar-
dium taken from patients with aortic stenosis, ventricular di-
lation, and established heart failure.
MATERIALS AND METHODS
Patient Selection
Under a protocol approved by the OxfordMedical Research Ethics Com-
mittee, myocardial biopsy specimens were obtained during aortic valve
replacement for aortic stenosis in 2 well-defined age- and sex-matched cat-
egories of consenting patients. The first group was characterized as having
aortic stenosis with echocardiographically and clinically (New York Heart
Association) well-preserved LV function. Primarily given diagnoses during
unrelated surgical work-up, indications for surgical intervention in this
group primarily comprised optimization before anesthetic, tight stenosis,
or both. The second group had aortic stenosis with impaired (decompen-
sated) LV function, together with established clinical heart failure (Table 1).
Patients with coronary artery disease were excluded.Medical regimens were
noted, with no overall difference between the surgical groups. All patients
underwent preoperative transthoracic echocardiographic analysis to quan-
tify peak transvalvular gradient, LV function, and LV dimensions. LV di-
mensions were measured on parasternal M-mode views taken at the level
of the chordae tendinae. The heart failure group contained 15 patients.
Those with preserved LV function were designated the nonfailing group
(n¼ 16). A control group of LV biopsy specimens was obtained from struc-
turally normal unmatched donor hearts that were not used for transplanta-
tion (n ¼ 6).
The biopsy specimens, weighing at least 2 g, were taken from the inter-
ventricular septum in the LV outflow tract beneath the right coronary cusp
and away from conduction tissue. All myocardial biopsy specimens were
immediately snap-frozen in liquid nitrogen and stored at80C.
Protein Extraction and Western Blotting
Protein was extracted into buffer (8 mol/L urea, 2% sodium dodecylsul-
fate [SDS], 10 mmol/L CHAPS, and 250 mmol/L Tris, pH 8.0), and the pro-
tein concentration of each sample was determined by using the Bio-Rad
(Hercules, Calif) protein assay. FHL2 and enzyme levels in myocardial
TABLE 1. Preoperative echocardiographic and NYHA assessment of
patient groups
Donor Nonfailing Failing
P
value*
Normal
range
No. of patients 6 16 15 NA
Male/female sex 4/2 9/7 7/8
Diagnosis NA AS AS
Age (y) 36  10 62  15 60  18 NS
LV end-diastolic
diameter (cm)
ND 4.8  0.5 6.4  0.5 .002 3.5–5.6
LV end-systolic
diameter (cm)
ND 2.8  0.4 4.3  0.5 .004 2.5–4.1
LVEF (%) ND 58  5 35  5 .009 55–75
Peak transvalvular
gradient (mm Hg)
ND 83  25 86  26 .83
NYHA class NA 1.4 2.9 .011
Values are presented as means  standard deviation.
NYHA, New York Heart Association; NA, not applicable; AS, aortic stenosis; NS, not
significant (P>.05); LV, left ventricular; ND, Not Determined; LVEF, left ventricular
ejection fraction. *P value, failing group compared with nonfailing group.rgery c April 2009
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mg) of protein were separated by means of electrophoresis on 12% SDS–
polyacrylamide gels and blotted onto nitrocellulose according to standard
protocols. FHL2 was detected with a mouse mAb, and standard mouse an-
tibodies against PFK2, AK, and CK-M (AbCam, Cambridge, Mass) were
used to detect these enzymes. Gel loading was confirmed by reprobing blots
with a b-actin antibody (AbCam). Blots were probed with a horseradish
peroxidase–conjugated secondary antibody (DakoCytomation, Glostrup,
Denmark) and analyzed by means of chemiluminescence (Amersham Bio-
sciences, Piscataway, NJ) on a densitometer (Bio-Rad) to allow calculation
of the intensity of each target band relative to b-actin by using proprietary
software.
Immunofluorescence
Cryosections (5 mm) were cut from frozen tissue and fixed in 4% para-
formaldehyde before solubilization in 0.1% triton X-100 in phosphate-buff-
ered saline (PBS). Sections were blocked with 10% fetal calf serum in PBS
and 0.1% Tween 20. Standard staining procedures were used. All washes
were performed with PBS and 0.1% Tween 20. Slides were counterstained
with 40-6-diamidino—2-phenylindole, dihydrochloride (DAPI); Alexa-
Fluor488-Phalloidin (Molecular Probes, Eugene, Ore); or both. A rabbit
anti-FHL2 polyclonal antibody10 was detected with a goat anti-rabbit IgG
conjugated to AlexaFluor546 (Molecular Probes). The Golgi apparatus
complex was stained with anti-Golgin p97 (Molecular probes). Standard
protocols were used for immunofluorescent detection of AK, PFK2, and
CK-M. Control staining with only secondary antibodies was performed
on each section. Confocal microscopy was performed with a Bio-Rad con-
focal microscope. A stack of 1.0-mm-thick sections were recorded, and at
least 3 different fields were examined for each sample.
Coimmunoprecipitation Assay
Protein was extracted into IP buffer (10 mmol/L N-2-hydroxyethylpiper-
azine-N-2-ethanesulfonic acid [pH 7.4], 100 mmol/L KCl, 5 mmol/L
MgSO4, 0.5% NP-40, 50 mmol/L ZnSO4, and 1 mmol/L dithiothreitol)
and separated by means of centrifugation at 13,000g for 5 minutes at 4C.
Protein concentration in the supernatant was measured as above. For each
assay, 750 mg of protein was incubated with 2.0 mg of the appropriate anti-
body for 2 hours at 4C, after which 10 mL of 50% Protein A agarose was
added and the mixture was incubated overnight at 4C with rotation. Beads
were washed 3 times in IP buffer and 3 times in IP buffer with 250 mmol/L
KCl, and then protein was resuspended in Laemmli buffer, denatured, and
electrophoresed on a 12% SDS–polyacrylamide gel. Immunoblotting was
performed as described above.
Enzyme Assays
Enzyme activities were measured from tissue extracted with PBS (pH 7.4),
0.5%NP-40, and10% glycerol. All extractswere desaltedwith a 7000molec-
ularweight (MW)cutoffmatrix ina0.5-mLspin column (Pierce, Inc,Cheshire,
United Kingdom) to remove contaminating small molecules, such as sugars,
nicotinamide adenine dinucleotide, reduced nicotinamide adenine dinucleo-
tide,ADP,orATP.Spectrophotometric enzyme-linkedassay forPFK2activity
was performed as previously described.11 A luminescence-based AK assay kit
(BioVision,Mountain View, Calif) was used for AK activity, according to the
manufacturers’ protocol; the initial AK assay was repeated in the presence of
50 mmol/L P1,P5-bis(adenosine)-50-pentaphosphate, and activity measured in
the presence of this inhibitor was subtracted from total activity to correct for
any non–AK-mediated activity. CK activity was measured according to the
protocol of Bishop and colleagues12 but with the addition of 50 mmol/L
P1,P5-bis(adenosine)-50-pentaphosphate A to inhibit AK activity.
Statistical Analysis
Data are expressed as means  standard deviation. Comparisons were
performed by using the Student’s t test or analysis of variance with the
post hoc Student–Newman–Keuls test where appropriate.The Journal of Thoracic andRESULTS
Changes in FHL2, AK, CK-M, and PFK2 Protein
Levels in Cardiac Hypertrophy and Heart Failure
Western blot analysis (Figure 1, A) shows that FHL2 levels
are maintained in hypertrophied LV tissue but reduced by
53% in failing hearts (Figure 1, B). Similarly, AK and PFK2
levels are decreased in failing hearts compared with those
seen in the control group (48% and 57% reduction, respec-
tively; Figure 1,C andD). There are no significant differences
in CK-M levels between groups, although there is a trend to-
ward reduced expression in failing hearts (Figure 1, E).
Pattern of FHL2 Expression Is Disrupted in the
Failing Ventricle
The distinctive FHL2 cross-striation pattern is observed in
normal and hypertrophied LV sections (Figure 2, A and B),
but this pattern is disrupted in failing LV sections: FHL2 is
not localized to the sarcomere with a cross-striated appear-
ance, but FHL2-specific staining is predominantly in cyto-
plasmic foci, many of which are adjacent to DAPI-stained
nuclei and reminiscent of Golgi apparatus (Figure 2, C). Co-
localization of FHL2 with Golgi apparatus is observed in the
failing group (Figure 3). This was consistently found at each
1-mm level in each section; in every failing LV section, the
FHL2 signal was predominantly colocalized with the Golgi
apparatus, although some of the Golgi apparatus had no
FHL2 staining. This is in contrast to the FHL2 staining of
the nonfailing groups, in which FHL2 was clearly seen
only in the previously observed striated pattern. The nega-
tive controls (secondary antibody only) showed no distinct
staining, and no Golgi apparatus localization of FHL2 was
observed in the nonfailing group (data not shown).
AK, CK-M, and PFK2 Interactions with FHL2
FHL2 binds with AK, CK-M, and PFK in the normal left
ventricle, and these interactions are maintained in hypertro-
phied and failing hearts despite the altered subcellular distri-
bution of FHL2 (Figure 4). Immunofluorescence for AK,
CK-M, and PFK2 (Figure 5) shows that all 3 enzymes mirror
FHL2 localization to the Golgi apparatus in the failing heart;
this pattern is observed at each level in all sections.
Enzyme Activities
PFK2 activity is reduced to 76% of control value in the
hypertrophied left ventricle and further decreased to 56%
in failing hearts. AK activity is decreased to 58% of control
value in hypertrophied and failing hearts. CK-M activity is
not altered in hypertrophied or failing hearts (Table 2).
DISCUSSION
FHL2 is a member of the four-and-a-half LIM domain
protein subfamily found in the earliest identifiable cardiac
precursor cells but restricted primarily to cardiomyocytes
in the adult,13 where it is located mainly at the Z-disc.Cardiovascular Surgery c Volume 137, Number 4 855
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FIGURE 1. Four-and-a-half LIM-protein 2 (FHL-2), adenylate kinase (AK), and phosphofructokinase 2 (PFK2) levels are significantly decreased in the
failing human heart. A, RepresentativeWestern blot of FHL2 in patients from the donor, nonfailing, and failing groups. b-Actin was used as a loading control.
Each lane represents a different heart. A selection of patients is shown. Densitometric analyses of blots were performed, and the ratio of protein band intensity
to b-actin band intensity was used to compare relative amounts of each protein. FHL2 levels were decreased by 53% compared with normal levels (B). AK
levels decreased by 48% (C) and PFK2 levels decreased by 57% (E) compared with levels in the control group. CK-M levels decreased slightly (D), but this
was not statistically significant. *P< .05.Several LIM domain proteins have roles in the development
and maintenance of cellular architecture through myofibril
adherence to the cytoskeleton. The Z-disc localization of
FHL2 is shared with muscle LIM protein, the expression
of which is vital for the structural organization of myofibrils,
with muscle LIM protein–deficient mice displaying disrup-
ted cytoarchitecture, dilated cardiomyopathy, and heart fail-
ure.14 A mouse knockout for the LIM protein Alp has right
ventricular cardiomyopathy.15
Lange and associates4 proposed that FHL2 acts as a spe-
cific adaptor protein to couple metabolic enzymes to sites of856 The Journal of Thoracic and Cardiovascular Suhigh energy consumption within the sarcomere through the
interaction with titin. FHL2 mutations affect the binding to
both N2B and its 2 regions of titin, leading to impaired re-
cruitment of metabolic enzymes to the cardiac sarcomere
and hence to cardiac failure. These observations led to the
suggestion that cardiac dysfunction in heart failure might
partly result from the interaction between sarcomere and
stretch-dependent signaling molecules.2
The N2B region of titin not only determines the elastic
properties of the sarcomere, it also relates to the ischemic
stress and cardiac hypertrophy responses through its bindingrgery c April 2009
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DFIGURE 2. Four-and-a-half LIM-protein 2 (FHL2) accumulates in discrete cytoplasmic foci in failing human hearts. Representative immunofluorescence
microscopic analysis of FHL2 in donor (A), nonfailing (B), and failing (C) left ventricular myocardium. FHL2 (red) in cardiomyocytes from patients with
preserved myocardial function (nonfailing group) shows a regular staining pattern indicated by arrowheads and the enlarged section of the merge panel. FHL2
in cardiomyocytes from patients in the failing group is sequestered in discrete cytoplasmic foci (arrows). Phalloidin staining (green) was used to identify
cardiomyocytes, and all sections were counterstained with DAPI (blue).proteins aB-cristalin and FHL2, respectively. Radke and co-
workers16 found that FHL2 protein was downregulated on
deletion of its binding site within the N2B region of titin.
These authors suggest that the interaction of N2B and
FHL2 provides a novel regulatory pathway to control the bal-
ance of hypertrophy and atrophy in the heart. This suggestion
is reinforced by the finding that patientswith amutation in the
titin N2B region (S3799Y) have hypertrophic cardiomyopa-
thy associated with an increased binding of FHL2 to titin.3
Titin therefore appears to be a key component in the assem-
bly, force transmission, andmaintenance of resting tension in
the sarcomere and tethers many proteins, including FHL2, in
the sarcomere. Accordingly, abnormalities in the sarcomeric
proteins interacting with titin/connectin cause hereditary
dilated cardiomyopathy.
Previous research into the role of FHL2 in the failing my-
ocyte is limited. FHL2-null mice have greater cardiac hyper-
trophic responses compared with those of wild-type control
animals after catecholamine infusion17 but not when sub-
jected to pressure overload by means of aortic banding.13The Journal of Thoracic andFHL2 specifically attenuates the transcriptional activator
function of extracellular signal-regulated kinase (ERK) be-
cause it blocks the mitogen-activated protein kinase kinase
1–ERK1/2–mediated hypertrophic response of the atrial na-
triuretic factor promoter.18 The disparate hypertrophic re-
sponse in gene-targeted mice might reflect differences in
signaling pathways involved in pressure overload and cate-
cholamine-induced hypertrophy. However, FHL2 acts as
both a transcriptional coactivator10 and corepressor.19 This
might also be an explanation for different hypertrophic re-
sponses in FHL2 gene–targeted animals.
Localization of metabolic enzymes to metabolically ac-
tive regions of the sarcomere is necessary for energy provi-
sion during contraction.5 This is demonstrated by a study
fromWojtas and associates,20 in which transgenic Drosoph-
ila constructed with glycolytic enzymes unable to localize
within the sarcomeres of their flight muscles were unable
to fly despite normal protein and activity levels. Diffusional
ATP/ADP exchange does not allow rapid and efficient
intracellular communication.5,6,21 Reactions catalyzed byCardiovascular Surgery c Volume 137, Number 4 857
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fer of high-energy phosphoryls to ATPases to promote com-
munication between ATP-consuming and ATP-generating
processes.6,21 Our hypothesis was that FHL2 plays an im-
portant role as an adaptor protein, coupling metabolic en-
zymes to titin, and that this situation might be disturbed in
the transition between compensatory myocardial hypertro-
phy and heart failure. Although our histologic observations
do not prove that FHL2 localization influences high energy
metabolism or causes heart failure, the altered localization,
along with the maintenance of FHL2 interactions with CK,
AK, and PFK2, suggests that FHL2 is worthy of further in-
vestigation, at least as a mediator of high energy metabolism
in the septal wall.
Through its role as an adaptor protein, FHL2 might play
a part in human cardiomyocyte contractility and is altered
in heart failure. In clinically well-categorized patient popula-
tions with aortic stenosis, we showed significantly decreased
FHL2 expression in failing hearts compared with that seen in
those with well-preserved left ventricular function or in
healthy control hearts (Figure 1). FHL2 joins an array of pro-
teins with altered expression in heart failure; further work to
clarify the level at which downregulation occurs will help de-
termine the role of FHL2 in heart failure signaling. Neverthe-
less, our main hypothesis focused on the cytoarchitectural
consequences of altered FHL2 expression. Consistent with
FIGURE 3. Four-and-a-half LIM-protein 2 (FHL2) colocalizes with the
Golgi-specific marker Golgin97 in cardiomyocytes from the failing group.
Sections were stained for FHL2 (red) and Golgin97 (green) and counter-
stained with DAPI. The majority of FHL2 staining is present in the Golgi
(arrowheads), but not all Golgi have FHL2 staining (arrows). A 1.0-mm
confocal section is shown.858 The Journal of Thoracic and Cardiovascular Surprevious studies, our findings confirmed the localization pat-
tern of FHL2 for healthy hearts.We also showed, using coim-
munoprecipitation from human tissue, that AK, CK-M, and
PFK2 are bound to FHL2 at the sarcomere. Lange and col-
leagues4 have previously suggested a role for FHL2 as an
adaptor molecule linking these enzymes to metabolically ac-
tive compartments during contraction. Similar but spatially
distinct roles for FHL2 as an adaptor/docking protein have
been identified, including cell adhesion22 and linkage of
voltage-gated ion channels to the cytoskeleton.23
Our results and those of Wojtas and associates20 indicate
that the mechanisms that supply ATP to ATPases for muscle
contraction require a highly organized cellular system. By
comparing the subcellular localization of FHL2 in healthy
FIGURE 4. Adenylate kinase (AK), creatine kinase isoform M (CK-M),
and phosphofructokinase 2 (PFK2) maintain their interaction with four-
and-a-half LIM-protein 2 (FHL2) in the failing heart. Coimmunoprecipita-
tion from extracts of patient hearts from each group shows that AK, CK-M,
and PFK2 are in a complex with FHL2. A representative result is shown.
Coimmunoprecipitations were performed from every sample.WB, Western
blot.gery c April 2009
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DFIGURE 5. Adenylate kinase (AK), creatine kinase isoform M (CK-M), and phosphofructokinase 2 (PFK2) are also present in the Golgi apparatus in the
failing heart. PFK2, AK, and CK-M (A, B, and C, respectively) all colocalize with Golgin97 (green) in the Golgi apparatus of failing cardiomyocytes. Con-
focal sections of 1.0 mm are shown. A representative result is shown. Staining was performed on every sample.human hearts with that of hearts with aortic stenosis, we
have shown that the orderly pattern in normal cardiomyo-
cytes is significantly disrupted in the failing group (Figure 2)
but not before the onset of failure in hypertrophied hearts. In
failing cardiomyocytes FHL2 showed absent or severely di-
minished localization to the Z-lines, instead accumulating in
the Golgi apparatus. AK, CK-M, and PFK2 remain bound to
FHL2 in all groups. The significance of the coimmunopreci-
pitation result is that it suggests FHL2 sequesters these
enzymes away from the sarcomere by means of direct inter-
action with them, as opposed to merely occupying the same
subcellular location, as indicated by the immunofluores-
cence. In nonischemic heart failure N2B and N2BA cardiac
titin isoforms had an N2BA/N2B expression ratio that was
significantly increased despite unchanged24 or decreased25
total titin content. Such alterations of the N2B isoform,
which binds FHL2,4 could contribute to the disruption of
FHL2, AK, CK-M, and PFK2 localization we observed in
failing cardiomyocytes.
The significance of Golgi apparatus accumulation is un-
certain, but it might simply reflect altered intracellular pro-
tein transport in failing myocytes. Defective intracellularThe Journal of Thoracic andprotein transport in heart failure can be seen by the inhibition
of Rab1-mediated endoplasmic reticulum-to-Golgi transport
in cardiomyocytes.26 A combination of altered titin isoform
expression and defective intracellular transport might lead to
the sequestration of FHL2, AK, CK-M, and PFK2 com-
plexes in the Golgi apparatus as heart failure progresses.
The failingmyocardium is characterized by changes in en-
ergy and substrate metabolism, although numerous human
studies have failed to consistently elucidate the direction of
alterations in glucose use. Several studies investigated the
role of individual enzymes in pathologic hearts. We have
TABLE 2. AK, CK, and PFK2 enzyme activities expressed per
milligram of extracted soluble protein
Enzyme Donor Nonfailing (AS) Failing (AS)
AK 5.72  1.03 3.36  1.18* 3.34  1.27*
PFK2 12.17  3.07 9.34  2.87* 6.87  1.93*y
CK 10.62  2.98 10.77  3.01 9.37  2.97
Enzyme activities are expressed as micromoles per minute per milligram. Values are
presented as means  standard deviation. *P< .05 versus control groups. yP< .05
versus the nonfailing group.Cardiovascular Surgery c Volume 137, Number 4 859
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activity has been shown to both increase and decrease6 in the
septal wall of failing myocardium. These disparities might
reflect a spectrum of responses to the degree of failure. En-
hanced glycolysis as a source of ATP has been proposed to
represent an adaptive mechanism in early heart failure; it is
possible that this adaptation is undermined by mislocaliza-
tion of glycolytic enzymes as decompensated heart failure
progresses. Association of enzymes with other proteins
might also influence their activities; the association of
glycolytic enzymes and band-3 protein or tubulin27 reduces
enzyme activity, whereas binding of 6-phosphofructo-
1-kinase to F-actin accelerates glycolytic flux in muscle.28
AK and PFK2 enzyme activities in our human samples
were decreased, whereas CK activity tended to decrease, al-
beit insignificantly, despite preserved binding to FHL2. This
implies allosteric activation of these enzymes is unusually,
albeit indirectly, related to localization by a modulating pro-
tein other than FHL2. The influence of titin–enzyme interac-
tion represents an important question in this context.
Furthermore, our results allow the distinction of 2 aspects
of enzyme function in cardiac muscle: localization and cat-
alytic activity. Catalytically active enzyme alone might not
be sufficient for muscle contraction, rather enzymes must
be properly localized to enable efficient function. Precisely
how disrupted localization manifests as poor contractile
function will be more elusive. Spatial difficulties in the de-
livery of reducing equivalents from the sarcomere to the mi-
tochondria,29 the (enigmatic) alterations in glycolytic flux,
and mechanical impairment of actin–myosin interaction29
are all potential mechanisms.
The precise timing and profile of FHL2 decrease in human
aortic stenosis remains to be elucidated. Donker and co-
workers30 showed a transient decrease in FHL2 expression
in dogs almost immediately after ventricular overload
induced by atrioventricular block. They suggest that FHL2
reduction at that stage contributes to hypertrophy through
derepression of the mitogen-activated protein kinase/ERK
pathway. Our study groups were similar in terms of trans-
valvular gradients and showed FHL2 expression to be pre-
served during compensated stenosis, suggesting that FHL2
expression might be transiently restored by normalization
of wall stress.
In summary, FHL2 expression and localization are pre-
served in human LV hypertrophy but disrupted in failing
cardiomyocytes. Sequestration of the enzymes PFK2, AK,
and CK-M by FHL2 appears responsible for their altered
subcellular localization in human heart failure, which is as-
sociated with reduced activities of PFK2 andAK. This might
yet prove to have important consequences for myocardial
energy metabolism in heart failure.
We thank Dr R. H. Schule of the University of Freiberg, Ger-
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